Clinical Trials Logo

Keratosis, Actinic clinical trials

View clinical trials related to Keratosis, Actinic.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06461442 Enrolling by invitation - Actinic Keratoses Clinical Trials

Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

Start date: July 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare the effectiveness and safety of two treatments-cryotherapy and 5-Fluorouracil (5-FU)-for actinic keratosis, a common skin condition caused by long-term sun exposure. Cryotherapy is a treatment that uses extreme cold produced by liquid nitrogen to freeze and destroy abnormal cells, and 5-FU is a topical cream applied to the skin to treat lesions by interfering with cell growth. The main questions this trial aims to answer are: - Which treatment, cryotherapy or 5-FU, is more effective in reducing the number of actinic keratosis lesions? - What are the side effects associated with each treatment? - How do these treatments impact patient satisfaction, cosmetic outcomes, and health-related quality of life? Participants will: - Undergo a baseline assessment where their demographics information such as age, sex, race, smoking status, and medical history are recorded, along with the number and severity of actinic keratosis lesions. - Receive both cryotherapy and 5-FU, with each treatment applied to different areas of their body. The area of the body to receive each treatment is decided by a random process (like flipping a coin). - Complete weekly surveys to monitor for side effects during and after the treatment period. - Return to the clinic for follow-up assessments at 3 months and 12 months.

NCT ID: NCT04814953 Enrolling by invitation - Clinical trials for Squamous Cell Carcinoma

HRQoL Keratinocyte Carcinomas

Start date: July 1, 2020
Phase:
Study type: Observational

Rationale: Keratinocyte skin cancer is known to influence the HRQoL in a specific way. Derived utility values are required for cost-effectiveness analyses of new interventions. However there is no sensitive tool to capture HRQoL that translates into utilities available. Objective: To document the exact HRQoL in patients with in KC using the generic EQ-5D-5L questionnaire, as well as the TTO, 15D and the BaSQoL questionnaire, and to develop health utilities based on these tools. Study design: Longitudinal observational study (at time 0 and time 0 +12 months). Study population: Patients aged ≥18 years consulting a dermatologist or their GP for diagnosis, treatment or follow-up of a (pre)malignant skin lesion(s).